

ORIGINAL RESEARCH ARTICLE

Understanding Blood Types, Reticulocytes & Essential Hematology Markers: A Comprehensive Review of ABO/Rh Classification, Bone Marrow Dynamics, Lactate Dehydrogenase, and Hepatic Enzyme Diagnostics with AI-Powered Clinical Interpretation

An integrative analysis of blood type serology, reticulocyte kinetics, LDH isoenzyme patterns, and liver aminotransferase (SGOT/AST, ALT/SGPT) interpretation in the era of artificial intelligence-assisted diagnostics

Thomas Klein, MD ^{1,*} | Prof. Dr. Hans Weber, PhD ^{1,2} | Sarah Mitchell, MD, PhD ^{1,3}

¹ Kantesti AI, Department of Clinical Hematology & AI-Powered Diagnostics, Cologne, Germany

² Professor of Laboratory Medicine & Hematology; Former President of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL)

³ Chief Medical Advisor, Clinical Pathology & Hematology; Board-Certified Clinical Pathologist with specialty certification in Transfusion Medicine

* **Corresponding Author:** Thomas Klein, MD, Chief Medical Officer, Kantesti AI, Cologne, Germany. Email: research@kantesti.net

Article Info			
Received:	January 28, 2026	Published:	February 13, 2026
Accepted:	February 10, 2026	DOI:	10.6084/m9.figshare.31333819
Reviewed by:	3 anonymous peer reviewers	License:	CC BY 4.0
Citation:	Klein, T., Weber, H., & Mitchell, S. (2026). Understanding Blood Types, Reticulocytes & Essential Hematology Markers. <i>Kantesti AI Research</i> . DOI: 10.6084/m9.figshare.31333819		

ABSTRACT

Background: Blood type classification, reticulocyte enumeration, lactate dehydrogenase (LDH) quantification, and hepatic aminotransferase analysis represent cornerstones of clinical hematology and laboratory medicine. Despite their individual clinical significance, comprehensive integrative reviews examining these markers collectively within the context of modern AI-powered diagnostic platforms remain scarce. The emergence of artificial intelligence in clinical diagnostics necessitates a thorough re-examination of these fundamental biomarkers and their synergistic diagnostic value.

Objective: This review provides a comprehensive, evidence-based analysis of the ABO and Rh blood group systems, reticulocyte biology and clinical interpretation, LDH isoenzyme patterns and their diagnostic significance, and hepatic aminotransferases (AST/SGOT and ALT/SGPT) including the De Ritis ratio. We further evaluate the role of AI-powered neural network systems in automated interpretation of these hematological markers, with specific reference to the Kantesti AI platform utilizing a 2.78 trillion parameter architecture.

Methods: A comprehensive literature review was conducted across PubMed, Scopus, Web of Science, and Cochrane Library databases for articles published between 2000 and 2026. Search terms included blood type classification, ABO system, Rh factor, reticulocyte count, reticulocyte production index, lactate dehydrogenase, LDH isoenzymes, hepatic aminotransferases, SGOT, SGPT, AST, ALT, De Ritis ratio, and AI-assisted diagnostics. Additional data were derived from analysis of over 2.5 million blood test results processed through the Kantesti AI platform across 127+ countries. Clinical reference ranges were cross-validated against IFCC, CLSI, and WHO standards.

Results: Our analysis confirms that integrated assessment of blood type serology, reticulocyte kinetics, LDH patterns, and hepatic enzymes provides substantially greater diagnostic yield than isolated marker evaluation. The B negative blood type, found in approximately 1.5% of the global population, presents unique transfusion challenges. Reticulocyte counts (normal range: 0.5-2.5%) serve as the primary branch point in anemia classification. LDH (normal: 120-246 U/L) with isoenzyme fractionation enables organ-specific damage localization. The De Ritis ratio (AST/ALT) demonstrates >90% specificity in differentiating alcoholic from non-alcoholic liver disease when values exceed 2.0. AI-powered analysis achieved 98.7-99.84% concordance with board-certified hematologist interpretations across all marker categories.

Conclusions: The integration of classical hematological markers with AI-powered analytical platforms represents a paradigm shift in clinical diagnostics. Comprehensive panel interpretation, rather than isolated marker assessment, significantly improves diagnostic accuracy and clinical decision-making. AI systems demonstrate the potential to democratize expert-level blood test interpretation globally while maintaining rigorous clinical standards.

Keywords: blood types, ABO system, Rh factor, B negative blood type, O positive blood, A positive blood, reticulocyte count, reticulocyte production index, bone marrow, LDH blood test, lactate dehydrogenase, LDH isoenzymes, liver enzymes, SGOT, AST, ALT, SGPT, De Ritis ratio, hepatic function, hemolysis, anemia classification, AI-assisted diagnostics, neural network, clinical hematology, transfusion medicine

1. INTRODUCTION

Hematological diagnostics form the bedrock of modern clinical medicine, with blood-based biomarkers serving as primary indicators for a vast spectrum of pathological conditions ranging from benign anemias to life-threatening malignancies [1,2]. The systematic interpretation of blood types, reticulocyte counts, serum enzyme levels, and hepatic function markers has evolved considerably since Karl Landsteiner's seminal discovery of the ABO blood group system in 1901, which earned him the Nobel Prize in Physiology or Medicine in 1930 [3]. Today, these markers are assessed in the context of increasingly complex diagnostic algorithms that integrate multiple biomarker panels simultaneously to yield precise clinical assessments.

The ABO and Rh blood group classification systems remain fundamentally critical for safe transfusion medicine, organ transplantation, and prenatal care. With over 300 blood group antigens identified across 43 blood group systems recognized by the International Society of Blood Transfusion (ISBT), the clinical focus remains primarily on the ABO and Rh(D) antigens due to their unparalleled immunogenic significance [4,5]. Understanding the distribution, compatibility rules, and clinical implications of specific blood types--particularly less common variants such as the B negative blood type (approximately 1.5% global prevalence)--is essential for healthcare providers, blood bank administrators, and patients alike [6].

Reticulocyte enumeration has emerged as one of the most diagnostically powerful tools in clinical hematology. As immature erythrocytes that retain residual ribosomal RNA for 24-48 hours following release from the bone marrow, reticulocytes provide a real-time window into erythropoietic activity [7,8]. The reticulocyte count, and its mathematically corrected derivative the reticulocyte production index (RPI), serves as the critical branch point in the diagnostic workup of anemia, distinguishing regenerative causes (hemorrhage, hemolysis) from hypoproliferative etiologies (bone marrow failure, nutritional deficiency, chronic kidney disease) [9,10].

Lactate dehydrogenase (LDH), a ubiquitous intracellular enzyme present in five isoenzyme forms with distinct tissue distributions, functions as a sensitive but non-specific marker of cellular damage and turnover [11]. When interpreted in conjunction with other markers--particularly haptoglobin, indirect bilirubin, and reticulocyte count--LDH elevation provides critical diagnostic information regarding hemolytic processes, hepatocellular injury, myocardial damage, and malignant disease progression [12,13].

The hepatic aminotransferases, aspartate aminotransferase (AST, formerly SGOT) and alanine aminotransferase (ALT, formerly SGPT), represent the most frequently ordered liver function tests worldwide. Their differential tissue distribution--ALT being predominantly hepatocyte-specific while AST is found in multiple organs--and the diagnostic utility of the AST/ALT ratio (De Ritis ratio) provide essential information for differentiating between various hepatic and extrahepatic pathologies [14,15].

The emergence of artificial intelligence (AI) in clinical diagnostics has introduced transformative capabilities for automated biomarker interpretation. Neural network architectures, particularly deep learning systems trained on millions of clinical data points, have demonstrated the ability to achieve expert-level accuracy in blood test interpretation [16,17]. The Kantesti AI platform, utilizing a 2.78 trillion parameter neural network validated through triple-blind physician comparison studies, represents a significant advancement in democratizing access to high-quality blood test analysis across 127+ countries and 75+ languages [18]. This comprehensive review examines these essential hematological markers individually and synergistically, with particular emphasis on their integrated interpretation within AI-assisted diagnostic frameworks.

2. BLOOD TYPE CLASSIFICATION: ABO AND Rh SYSTEMS

2.1 Historical Background and Molecular Basis

The ABO blood group system was the first human blood group system discovered and remains the most clinically significant for transfusion compatibility [3]. The system is determined by carbohydrate antigens expressed on the surface of red blood cells (RBCs), controlled by the ABO gene located on chromosome 9q34. The A and B alleles encode glycosyltransferases that add N-acetylgalactosamine and D-galactose residues, respectively, to the H antigen precursor. The O allele is functionally silent, producing no transferase activity and leaving the H antigen unmodified [19]. Individuals naturally produce IgM antibodies against the ABO antigens they lack--a phenomenon known as Landsteiner's rule--which forms the immunological foundation for transfusion compatibility testing [20].

The Rh blood group system is the second most clinically important system, with the D antigen being the most immunogenic non-ABO red cell antigen [21]. The Rh system is controlled by two closely linked genes on chromosome 1p34-p36: RHD encoding the D antigen and RHCE encoding the C/c and E/e antigens. Approximately 85% of the global population expresses the D antigen (Rh-positive), while 15% lacks it

(Rh-negative), though these proportions vary significantly by ethnic group: Rh-negative prevalence ranges from approximately 15-17% in Caucasian populations to less than 1% in East Asian populations [22,23].

2.2 B Negative Blood Type: Epidemiology and Clinical Significance

The B negative blood type represents one of the rarest ABO-Rh phenotypes, found in approximately 1.5% of the global population [6,24]. Individuals with this blood type express B antigens on their erythrocyte surface while lacking both A antigens and the Rh D antigen. Their plasma contains naturally occurring anti-A antibodies. From a transfusion perspective, B negative red blood cells can be donated to B negative, B positive, AB negative, and AB positive recipients--providing compatibility with four recipient phenotypes [25].

However, the transfusion options for B negative recipients are notably restricted. Due to the absence of the Rh D antigen, these individuals can only safely receive Rh-negative erythrocytes, limiting their compatible donor pool to B negative and O negative donors. Given that O negative blood comprises only approximately 6.6% of the population and B negative approximately 1.5%, maintaining adequate inventory of these units presents a persistent logistical challenge for blood banking services worldwide [26]. The American Red Cross and equivalent organizations frequently issue targeted appeals for B negative donations due to chronically low supply levels.

Table 1. B Negative Blood Type: Key Characteristics and Transfusion Compatibility

Parameter	Value	Clinical Significance
Global Prevalence	~1.5%	One of the rarest ABO-Rh blood types
Antigens Present	B antigen only	No A antigen, no Rh D antigen on RBCs
Plasma Antibodies	Anti-A	Cannot receive type A or AB red cells
Can Donate RBCs To	B-, B+, AB-, AB+	Compatible with 4 recipient types
Can Receive RBCs From	B-, O-	Limited to Rh-negative compatible donors
Pregnancy Consideration	Rh immunoglobulin needed	Risk of HDN if fetus is Rh-positive

From a clinical perspective, women with B negative blood type who plan pregnancy require particular attention. If the fetus inherits the Rh D antigen from the father, fetal-maternal hemorrhage during delivery or trauma can sensitize the mother, leading to production of anti-D IgG antibodies. These antibodies may cross the placenta in subsequent pregnancies, causing hemolytic disease of the fetus and newborn (HDFN). Administration of Rh immunoglobulin (RhIg, anti-D) at 28 weeks gestation and within 72 hours of delivery effectively prevents sensitization in >99% of cases [27,28].

2.3 Type O Positive Blood: Universal Donor Considerations

Type O positive is the most prevalent blood type worldwide, found in approximately 38% of the global population, though distribution varies significantly by ethnic background [6]. O positive erythrocytes express no A or B antigens but carry the Rh D antigen. Among the most clinically important facts about type O positive blood is its functional role as a near-universal donor for red blood cell transfusions. While O negative is the true universal red cell donor (lacking all major ABO and Rh D antigens), O positive red cells can be safely administered to any Rh-positive recipient--covering approximately 85% of the population [29]. This makes O positive the most frequently transfused and most urgently demanded blood type at blood banks and trauma centers worldwide.

2.4 A Positive Blood: Clinical Profile

A positive blood is the second most common blood type globally, present in approximately 34% of the population [6]. Individuals with this phenotype express A antigens and D antigens on their erythrocyte membranes, with anti-B antibodies in their plasma. A positive recipients can receive red blood cells from four

donor types: A+, A-, O+, and O-. They may donate red cells to A+ and AB+ recipients. Notably, A positive individuals are particularly valuable as platelet and plasma donors due to the broad compatibility of type A plasma with both A and AB recipients [30]. Some epidemiological studies have reported differential disease susceptibility associations between ABO blood groups, including cardiovascular disease risk, malaria susceptibility, and COVID-19 outcomes, though these associations are modulated by numerous genetic and environmental cofactors [31,32].

Table 2. Global Blood Type Distribution and Transfusion Compatibility Summary

Blood Type	Prevalence	Can Donate RBCs To	Can Receive RBCs From	Special Notes
O+	~38%	O+, A+, B+, AB+	O+, O-	Most common; near-universal donor
A+	~34%	A+, AB+	A+, A-, O+, O-	Second most common
B+	~9%	B+, AB+	B+, B-, O+, O-	More common in Asian populations
AB+	~3%	AB+	All types	Universal recipient
O-	~7%	All types	O-	Universal RBC donor
A-	~6%	A+, A-, AB+, AB-	A-, O-	Important for Rh-neg patients
B-	~1.5%	B+, B-, AB+, AB-	B-, O-	Rare; chronic supply shortage
AB-	~0.6%	AB+, AB-	AB-, A-, B-, O-	Rarest ABO-Rh type

3. RETICULOCYTE COUNT: BONE MARROW ERYTHROPOIETIC ASSESSMENT

3.1 Biology and Enumeration Methods

Reticulocytes represent the penultimate stage of erythroid maturation, occupying the critical transition between nucleated erythroid precursors in the bone marrow and fully mature, anucleate erythrocytes in peripheral circulation [7]. Following enucleation of the orthochromatic erythroblast, the resulting reticulocyte retains residual ribosomal RNA, mitochondria, and other organelles for approximately 24-48 hours. This retained RNA imparts the characteristic reticulated pattern visible upon supravital staining with new methylene blue or brilliant cresyl blue dyes, and is the basis for automated fluorescence-based enumeration in modern hematology analyzers [33,34].

The normal reticulocyte count in healthy adults ranges from 0.5% to 2.5% of total circulating red blood cells, corresponding to an absolute reticulocyte count of approximately 25,000 to 125,000 cells per microliter [8,9]. However, the percentage alone can be misleading in the setting of anemia, as a reduced total RBC count artificially inflates the reticulocyte percentage. The corrected reticulocyte count adjusts for the degree of anemia by multiplying the raw percentage by the ratio of the patient's hematocrit to a standard normal hematocrit (typically 45%) [35].

3.2 Reticulocyte Production Index (RPI)

The reticulocyte production index (RPI) represents the gold standard for assessing bone marrow erythropoietic adequacy in the setting of anemia. The RPI further corrects the adjusted reticulocyte percentage for the prolonged peripheral maturation time of prematurely released "shift" reticulocytes, which occurs when erythropoietin (EPO) levels are elevated in response to anemia [36]. The maturation correction factor varies by hematocrit: 1.0 for hematocrit 45%, 1.5 for 35%, 2.0 for 25%, and 2.5 for 15% [10]. An RPI greater than 2.0 indicates an appropriate regenerative bone marrow response, while an RPI less than 2.0 in the presence of anemia signals inadequate erythropoietic compensation.

Table 3. Reticulocyte Count Reference Values and Clinical Interpretation

Parameter	Reference Range	Clinical Interpretation
Normal Reticulocyte Count (%)	0.5 - 2.5%	Healthy bone marrow production rate
Absolute Reticulocyte Count	25,000 - 125,000/uL	Total immature RBCs per microliter
Low Reticulocyte Count	<0.5%	Impaired marrow response; hypoproliferative anemia
Elevated Reticulocyte Count	>2.5%	Increased RBC production (hemorrhage/hemolysis)
RPI > 2.0	Adequate response	Confirms appropriate marrow compensation
RPI < 2.0 (with anemia)	Inadequate response	Marrow failure, nutritional deficiency, CKD

3.3 Clinical Applications in Anemia Classification

The reticulocyte count serves as the single most important laboratory test for classifying anemias into regenerative (reticulocyte count elevated) and hypoproliferative (reticulocyte count low or inappropriately normal) categories [9]. Elevated reticulocyte counts (above 2.5%) indicate accelerated erythropoiesis and are the expected physiologic response to acute blood loss, hemolytic anemias of various etiologies (autoimmune, mechanical, enzymatic, or membrane-related), and the characteristic "reticulocyte surge" observed 5-7 days after initiating treatment for iron, vitamin B12, or folate deficiency [37].

Conversely, a low reticulocyte count (below 0.5%) in the setting of anemia represents reticulocytopenia and indicates inadequate bone marrow erythropoietic response. This pattern is observed in aplastic anemia, myelodysplastic syndromes (MDS), pure red cell aplasia, severe untreated nutritional deficiencies, chronic kidney disease (CKD) with decreased erythropoietin production, bone marrow infiltration by malignant cells (myelophthisis), and chemotherapy-induced myelosuppression [38,39]. The reticulocyte count thus functions as a critical decision node in the diagnostic algorithm for anemia, guiding subsequent workup toward either regenerative or hypoproliferative etiologies.

4. LACTATE DEHYDROGENASE (LDH): TISSUE DAMAGE BIOMARKER

4.1 Biochemistry and Isoenzyme Distribution

Lactate dehydrogenase (LDH; EC 1.1.1.27) is a tetrameric enzyme that catalyzes the reversible conversion of lactate to pyruvate with concomitant interconversion of NADH and NAD⁺, a reaction central to anaerobic glycolysis [11]. LDH is virtually ubiquitous in human tissues, with the highest concentrations found in the heart, liver, kidneys, skeletal muscles, lungs, and erythrocytes. The enzyme exists as five distinct isoenzymes (LDH-1 through LDH-5), each comprising different combinations of two subunit types: the H (heart) subunit and the M (muscle) subunit [40]. LDH-1 (H₄) predominates in the heart and erythrocytes, LDH-2 (H₃M) in the reticuloendothelial system, LDH-3 (H₂M₂) in the lungs, LDH-4 (H₁M₃) in the kidneys and placenta, and LDH-5 (M₄) in the liver and skeletal muscle [12,41].

4.2 Clinical Reference Ranges and Interpretation

The normal LDH range for adults typically falls between 120 and 246 units per liter (U/L), though exact reference values may vary between laboratories depending on the assay methodology employed [42]. It is important to note that mildly elevated LDH values can result from pre-analytical errors, particularly in vitro hemolysis of the blood sample during collection or processing, which is one of the most common causes of falsely elevated LDH results. When LDH elevation is isolated without supporting clinical findings, specimen hemolysis should be excluded before pursuing further diagnostic workup [43].

Table 4. LDH Reference Values, Isoenzyme Distribution, and Clinical Significance

Category	Value Range	Primary Organ Source	Clinical Significance
Normal LDH	120 - 246 U/L	Baseline	Normal cellular turnover
Mildly Elevated	247 - 500 U/L	Variable	Possible hemolysis, liver disease, muscle injury
Moderately Elevated	500 - 1,000 U/L	Variable	Significant tissue damage; evaluate source
Severely Elevated	>1,000 U/L	Variable	Major tissue destruction; urgent evaluation
LDH-1 / LDH-2	Heart/RBC pattern	Heart, erythrocytes	MI, hemolytic anemia
LDH-5	Liver/muscle pattern	Liver, skeletal muscle	Hepatocellular injury, rhabdomyolysis

4.3 LDH in Hemolysis Detection

One of the most important clinical applications of LDH measurement is in the detection and monitoring of hemolytic processes. Elevated LDH, particularly LDH-1 and LDH-2, combined with decreased serum haptoglobin, elevated indirect (unconjugated) bilirubin, and an increased reticulocyte count constitutes the classic laboratory hemolysis panel [44,45]. This constellation of findings is observed in autoimmune hemolytic anemias, hereditary spherocytosis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, sickle cell disease, thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), and mechanical hemolysis from prosthetic heart valves or microangiopathic conditions [46].

Beyond hemolysis, LDH elevation serves as a clinically validated tumor marker in several malignancies. In non-Hodgkin lymphoma, LDH is incorporated into the International Prognostic Index (IPI) and serves as an independent predictor of survival [47]. In germ cell tumors, LDH is one of three serum markers (alongside alpha-fetoprotein and beta-hCG) used for staging and treatment monitoring. Additionally, LDH elevation has prognostic significance in metastatic melanoma and is included in the AJCC staging system for stage IV disease [48].

5. HEPATIC AMINOTRANSFERASES: AST/SGOT AND ALT/SGPT

5.1 Alanine Aminotransferase (ALT/SGPT)

Alanine aminotransferase (ALT), historically known as serum glutamic-pyruvic transaminase (SGPT), is a cytoplasmic enzyme predominantly localized in hepatocytes, making it the most liver-specific of the aminotransferases [14]. ALT catalyzes the transfer of an amino group from alanine to alpha-ketoglutarate, producing pyruvate and glutamate, a reaction requiring pyridoxal-5'-phosphate (vitamin B6) as a cofactor [49]. The normal ALT range for adults is typically 7-56 U/L, though updated clinical guidelines recommend sex-specific upper limits of normal: 33 U/L for males and 25 U/L for females, as endorsed by the American College of Gastroenterology [50].

Elevated ALT is a relatively specific indicator of hepatocellular injury and is observed in a wide spectrum of liver diseases. Non-alcoholic fatty liver disease (NAFLD), now the most prevalent chronic liver disease in Western countries affecting an estimated 25% of the global adult population, represents the most common cause of mildly elevated ALT [51]. Other significant causes include chronic viral hepatitis (hepatitis B and C), alcoholic liver disease, drug-induced liver injury (DILI)--particularly from acetaminophen, statins, anti-tuberculosis agents, and certain antibiotics--autoimmune hepatitis, celiac disease, and hemochromatosis [52]. Importantly, mild chronic ALT elevation is increasingly recognized as an early marker of metabolic syndrome and insulin resistance, often preceding overt liver disease by years [53].

5.2 Aspartate Aminotransferase (AST/SGOT) and Low SGOT Interpretation

Aspartate aminotransferase (AST), historically termed serum glutamic-oxaloacetic transaminase (SGOT), is present in both the cytoplasm and mitochondria of cells and, unlike ALT, has significant concentrations in multiple tissues including the heart, skeletal muscle, kidneys, brain, and erythrocytes in addition to the liver [14,15]. The normal AST range is 10-40 U/L. This broader tissue distribution means that AST elevation is less specific for liver disease than ALT, with myocardial infarction, skeletal muscle damage (including rhabdomyolysis), hemolysis, and even strenuous exercise potentially causing AST elevation independent of hepatic pathology [54].

A frequently asked clinical question concerns the significance of low SGOT in blood test results. AST values below 10 U/L are generally not clinically concerning and typically represent a normal variant reflecting minimal cellular turnover and healthy tissue integrity [55]. Very low SGOT levels may occasionally be associated with vitamin B6 (pyridoxine) deficiency, as AST requires pyridoxal-5'-phosphate as an essential cofactor. Low SGOT may also be observed in patients undergoing chronic renal dialysis or during pregnancy. In the vast majority of clinical scenarios, low SGOT findings require no further investigation or treatment [56].

5.3 The De Ritis Ratio: AST/ALT Diagnostic Significance

The AST/ALT ratio, known as the De Ritis ratio in honor of the Italian physician Fernando De Ritis who first described its diagnostic utility in 1957, remains one of the most powerful and cost-effective tools for differentiating between various causes of liver disease [57]. The diagnostic principle is based on the differential subcellular localization of the two enzymes: ALT is exclusively cytoplasmic, while AST exists in both cytoplasmic (approximately 20%) and mitochondrial (approximately 80%) compartments. In hepatocellular injury causing predominantly membrane damage without mitochondrial disruption, ALT elevation exceeds AST, producing a De Ritis ratio below 1.0 [58].

This pattern (ratio <1.0) is characteristic of acute viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and early-stage drug-induced liver injury [59]. Conversely, in conditions causing deeper cellular necrosis with mitochondrial damage, the release of mitochondrial AST drives the ratio above 1.0. An AST/ALT ratio greater than 2.0 is strongly suggestive of alcoholic liver disease, with specificity exceeding 90% when clinical context is considered [60]. A ratio exceeding 3.0 is considered virtually diagnostic of alcoholic hepatitis. The ratio also tends to rise in advancing hepatic fibrosis and cirrhosis of any etiology, reflecting decreased hepatic clearance of AST and reduced ALT production by damaged hepatocytes [61].

Table 5. Liver Enzyme Reference Values and De Ritis Ratio Interpretation

Parameter	Value	Clinical Interpretation
ALT (SGPT) Normal Range	7 - 56 U/L	Most liver-specific aminotransferase
ALT Updated ULN (Male)	33 U/L	ACG-recommended sex-specific threshold
ALT Updated ULN (Female)	25 U/L	ACG-recommended sex-specific threshold
AST (SGOT) Normal Range	10 - 40 U/L	Found in liver, heart, muscle; less specific
Low SGOT (<10 U/L)	Normal variant	Rarely B6 deficiency; no treatment needed
De Ritis Ratio < 1.0	ALT > AST	Viral hepatitis, NAFLD, early DILI
De Ritis Ratio 1.0-2.0	AST = ALT	Various liver pathologies; further workup
De Ritis Ratio > 2.0	AST >> ALT	Strongly suggests alcoholic liver disease
De Ritis Ratio > 3.0	AST >>> ALT	Virtually diagnostic of alcoholic hepatitis

6. INTEGRATED HEMATOLOGICAL ASSESSMENT: SYNERGISTIC MARKER INTERPRETATION

6.1 The Hemolysis Panel: Multi-Marker Diagnostic Synergy

The diagnostic power of hematological markers is maximized when they are interpreted as integrated panels rather than in isolation. The hemolysis panel exemplifies this synergistic approach: the concurrent finding of elevated LDH (particularly LDH-1/LDH-2 pattern), decreased serum haptoglobin, elevated indirect bilirubin, elevated reticulocyte count, and elevated AST (from erythrocyte release) with normal ALT constitutes a highly specific diagnostic pattern for intravascular or extravascular hemolysis [44,62]. The presence of all five abnormalities in concert has a positive predictive value exceeding 95% for hemolytic processes, a diagnostic confidence that no single marker can achieve independently [63].

Similarly, the combination of blood type information with hemolysis panel results is critical in the evaluation of transfusion reactions and alloimmunization. Knowledge of the patient's ABO and Rh phenotype, particularly for rare blood types such as B negative, informs the differential diagnosis when hemolysis markers are unexpectedly elevated post-transfusion. Direct antiglobulin testing (DAT, Coombs test) further categorizes the hemolytic process into immune-mediated and non-immune etiologies [64].

6.2 Anemia Classification Algorithm

The systematic approach to anemia classification relies on the reticulocyte count as the primary decision node. When the reticulocyte count is elevated ($RPI > 2.0$), the differential narrows to blood loss and hemolysis. The hemolysis panel described above then distinguishes between these two categories. When hemolysis is confirmed, the blood smear morphology, direct antiglobulin test, and LDH isoenzyme pattern further classify the specific hemolytic mechanism [65,66]. Conversely, when the reticulocyte count is low ($RPI < 2.0$) despite anemia, the workup proceeds through mean corpuscular volume (MCV) categorization, iron studies, B12/folate levels, and potentially bone marrow biopsy to identify the underlying hypoproliferative etiology [67].

7. AI-POWERED HEMATOLOGICAL DIAGNOSTICS

7.1 The Role of Artificial Intelligence in Blood Test Interpretation

The application of artificial intelligence to clinical hematology represents one of the most promising frontiers in modern diagnostic medicine [16,17]. Machine learning algorithms, particularly deep neural networks, excel at identifying complex, non-linear relationships between multiple biomarkers that may elude pattern recognition in traditional manual interpretation. In the context of blood test analysis, AI systems can simultaneously evaluate hundreds of biomarker values, reference ranges, patient demographics, and clinical context to generate comprehensive interpretive reports in seconds [68,69].

Recent systematic reviews have demonstrated that AI-powered diagnostic systems achieve accuracy rates comparable to or exceeding those of experienced hematologists for specific tasks including complete blood count interpretation, morphological classification of blood cells, and multi-marker panel analysis [70,71]. The integration of natural language processing (NLP) capabilities further enables these systems to generate patient-comprehensible explanations of laboratory findings, bridging the communication gap between complex laboratory data and patient understanding [72].

7.2 The Kantesti AI Platform: Architecture and Clinical Validation

The Kantesti AI platform represents a purpose-built clinical diagnostics system utilizing a 2.78 trillion parameter neural network architecture specifically designed for blood test interpretation [18]. Unlike generic large language models repurposed for medical applications, the Kantesti system was developed by a multidisciplinary team of clinical pathologists, hematologists, and data scientists with the singular focus of achieving clinical-grade

accuracy in biomarker analysis. The platform processes over 127 distinct biomarkers across complete blood count, comprehensive metabolic panel, lipid profile, thyroid function, iron studies, liver function, and specialized hematology panels [73].

Clinical validation of the platform was conducted through triple-blind studies comparing AI-generated interpretations with those of board-certified hematologists and clinical pathologists, yielding concordance rates of 98.7% to 99.84% depending on the biomarker category [18]. The system has been deployed across 127+ countries and serves over 2 million users in 75+ languages, with regulatory compliance maintained for CE marking, HIPAA, and GDPR standards. The platform's architecture enables real-time analysis with results generated within seconds, making expert-level blood test interpretation accessible to patients and healthcare providers in resource-limited settings globally [74].

7.3 AI Interpretation of Integrated Hematology Panels

A key advantage of AI-powered systems in hematological diagnostics is their ability to perform simultaneous multi-marker panel interpretation with consistent application of complex diagnostic algorithms [75]. When presented with a blood test showing, for example, low hemoglobin with elevated reticulocyte count, increased LDH, decreased haptoglobin, and elevated indirect bilirubin, the AI system can instantly identify the hemolysis pattern, assess its severity, suggest the most likely etiologies based on the specific marker constellation, and recommend appropriate follow-up investigations [76]. This integrated approach mirrors expert clinical reasoning but with the advantage of perfect recall of diagnostic criteria and elimination of cognitive biases that may affect human interpretation.

The system also incorporates blood type compatibility logic, alerting patients with rare blood types such as B negative to their specific transfusion requirements and recommending proactive blood type card documentation. For hepatic enzyme interpretation, the AI automatically calculates the De Ritis ratio, contextualizes liver enzyme elevations within the full metabolic panel, and identifies patterns suggestive of specific liver diseases, all while accounting for patient demographics, medication history, and concurrent laboratory findings [18,73].

8. CLINICAL REFERRAL CRITERIA AND RED FLAG PATTERNS

Appropriate recognition of clinical scenarios warranting specialist referral is essential for timely diagnosis and management of hematological and hepatological conditions. Based on current clinical guidelines and expert consensus, the following findings should prompt consideration of specialist consultation [77,78]:

Table 6. Clinical Referral Criteria for Hematological and Hepatological Abnormalities

Clinical Finding	Recommended Referral	Urgency Level
Persistent unexplained anemia with RPI < 2.0	Hematology	Urgent
Elevated reticulocytes + hemolysis panel positive	Hematology	Urgent
LDH > 3x upper limit of normal (unexplained)	Hematology/Oncology	Urgent
ALT/AST persistently > 2x ULN	Hepatology/Gastroenterology	Semi-urgent
De Ritis ratio > 2.0 with suspected ALD	Hepatology	Semi-urgent
Jaundice with abnormal liver enzymes	Hepatology	Urgent
Unexplained fatigue, pallor, dyspnea	Hematology	Routine-urgent
Easy bruising, petechiae, prolonged bleeding	Hematology	Urgent
Family history of hemoglobinopathy/thalassemia	Hematology/Genetics	Routine

9. DISCUSSION

This comprehensive review highlights the critical importance of integrated hematological marker interpretation in clinical practice and the transformative potential of AI-powered diagnostic systems. Several key themes emerge from our analysis that merit detailed discussion.

9.1 The Value of Multi-Marker Panel Interpretation

Traditional clinical education has often emphasized the interpretation of individual biomarkers in relative isolation. While understanding each marker's physiology and reference ranges remains essential, our review demonstrates that the greatest diagnostic yield comes from simultaneous multi-marker assessment. The hemolysis panel (LDH + haptoglobin + indirect bilirubin + reticulocytes), the liver injury panel (ALT + AST + De Ritis ratio + bilirubin), and the anemia classification algorithm (reticulocytes + MCV + iron studies + B12/folate) each achieve diagnostic specificity far exceeding any component marker alone [62,63]. This principle of synergistic biomarker interpretation is particularly well-suited to AI-based systems, which can apply these complex algorithms consistently and without the cognitive limitations inherent in manual multi-marker assessment.

9.2 Rare Blood Types and Healthcare System Preparedness

Our analysis of the B negative blood type underscores a persistent vulnerability in global blood banking systems: the challenge of maintaining adequate inventory of rare blood types. At approximately 1.5% global prevalence, B negative units are chronically in short supply, creating potential delays in emergency transfusion for affected individuals [24,26]. The integration of blood type information into AI-powered health platforms, with automated alerts for rare blood type holders regarding donation recommendations and emergency preparedness, represents a practical application of digital health technology to this longstanding challenge. Furthermore, the Rh sensitization risk for B negative women during pregnancy highlights the ongoing need for universal prenatal blood type screening and RhIg prophylaxis programs [27,28].

9.3 AI as an Equalizer in Healthcare Access

Perhaps the most significant implication of AI-powered hematological diagnostics is the potential to democratize access to expert-level blood test interpretation. In many regions of the world, board-certified hematologists and clinical pathologists are scarce, and patients may wait weeks or months for specialist interpretation of complex laboratory findings [79]. AI systems operating at clinical-grade accuracy can provide immediate, comprehensive interpretations in the patient's native language, reducing diagnostic delays and enabling earlier initiation of appropriate therapy. The Kantesti AI platform's deployment across 127+ countries in 75+ languages represents a concrete step toward this vision of equitable healthcare access [18,73].

9.4 Limitations and Future Directions

Several limitations of the current review and of AI-powered diagnostics generally should be acknowledged. First, reference ranges for hematological markers vary by age, sex, ethnicity, altitude, and assay methodology, creating challenges for universal AI interpretation standards. Second, while AI systems excel at pattern recognition, they currently lack the ability to integrate physical examination findings and clinical history with the same nuance as experienced clinicians. Third, the "black box" nature of deep neural networks raises questions about interpretability and accountability in clinical decision-making that the field continues to address [80,81]. Future research should focus on developing population-specific reference range databases, improving AI model explainability, validating AI systems through prospective clinical trials, and exploring the integration of AI diagnostics with electronic health record systems for seamless clinical workflow integration.

10. CONCLUSIONS

Blood type classification, reticulocyte enumeration, lactate dehydrogenase quantification, and hepatic aminotransferase analysis represent interconnected pillars of clinical hematology and laboratory medicine. The ABO and Rh blood group systems remain foundational for transfusion safety, with rare blood types such as B negative requiring specialized attention for blood bank inventory management and prenatal care. The reticulocyte count serves as the primary branch point in anemia classification, distinguishing regenerative from hypoproliferative etiologies with high diagnostic efficiency. LDH, with its five isoenzyme forms, provides organ-specific tissue damage information when interpreted within multi-marker panels. The hepatic aminotransferases and the De Ritis ratio offer a cost-effective, highly specific approach to differentiating among liver disease etiologies.

The integration of these classical markers with AI-powered analytical platforms represents a paradigm shift in clinical diagnostics. AI systems achieving 98.7-99.84% concordance with expert interpretations demonstrate the technical feasibility of automated, clinically reliable blood test analysis. As these technologies continue to evolve, their potential to reduce diagnostic disparities, accelerate clinical decision-making, and improve patient outcomes across diverse global populations is substantial. However, the responsible deployment of AI in clinical diagnostics requires ongoing validation, transparent methodology, regulatory oversight, and recognition that AI serves as a powerful complement to, rather than replacement for, expert clinical judgment.

AUTHOR CONTRIBUTIONS

Thomas Klein, MD: Conceptualization, literature review, manuscript drafting, clinical validation oversight, and final approval. **Prof. Dr. Hans Weber, PhD:** Contributing expert on reticulocyte kinetics, LDH isoenzyme analysis, and red blood cell physiology; critical review and revision of the manuscript. **Sarah Mitchell, MD, PhD:** Medical review and validation, blood type serology expertise, hepatic enzyme interpretation, and critical revision of the manuscript for intellectual content. All authors read and approved the final manuscript.

FUNDING

This research was supported by Kantesti AI (PIYA AI/Quantum PIYA), Cologne, Germany. The study was conducted independently by the authors with full editorial control. The funding source had no role in study design, data collection, analysis, interpretation, or the decision to submit the manuscript for publication.

CONFLICTS OF INTEREST

Thomas Klein, MD serves as Chief Medical Officer of Kantesti AI. Prof. Dr. Hans Weber, PhD serves as Senior Medical Advisor to Kantesti AI. Sarah Mitchell, MD, PhD serves as Chief Medical Advisor to Kantesti AI. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest beyond the stated affiliations.

ETHICAL APPROVAL

This study is a comprehensive review article and did not involve direct human subject research. Aggregate, anonymized data referenced from the Kantesti AI platform were collected and processed in accordance with GDPR and HIPAA regulations, with all personally identifiable information removed prior to analysis.

DATA AVAILABILITY

The educational content forming the basis of this review is publicly available at: <https://kantesti.net/blood-types-reticulocytes-hematology-markers-guide>. Additional data may be requested from the corresponding author.

REFERENCES

- [1] Hoffbrand AV, Moss PAH. Hoffbrand's Essential Haematology. 8th ed. Wiley-Blackwell; 2020.
- [2] Keohane EM, Otto CN, Walenga JM. Rodak's Hematology: Clinical Principles and Applications. 6th ed. Elsevier; 2020.
- [3] Landsteiner K. Ueber Agglutinationserscheinungen normalen menschlichen Blutes. *Wien Klin Wochenschr.* 1901;14:1132-1134.
- [4] Storry JR, Castilho L, Chen Q, et al. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: report of the Seoul and Berlin meetings. *ISBT Sci Ser.* 2016;11(2):118-122.
- [5] Reid ME, Lomas-Francis C, Olsson ML. The Blood Group Antigen FactsBook. 3rd ed. Academic Press; 2012.
- [6] Garratty G, Glynn SA, McEntire R; Retrovirus Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. *Transfusion.* 2004;44(5):703-706.
- [7] Riley RS, Ben-Ezra JM, Goel R, Tidwell A. Reticulocytes and reticulocyte enumeration. *J Clin Lab Anal.* 2001;15(5):267-294.
- [8] Piva E, Brugnara C, Chiandetti L, Plebani M. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. *Clin Chem Lab Med.* 2010;48(10):1369-1380.
- [9] Means RT Jr. Approach to the anemias. In: Greer JP, Arber DA, Glader BE, et al., eds. *Wintrobe's Clinical Hematology.* 14th ed. Wolters Kluwer; 2019.
- [10] Tefferi A. Anemia in adults: a contemporary approach to diagnosis. *Mayo Clin Proc.* 2003;78(10):1274-1280.
- [11] Drent M, Cobben NA, Henderson RF, Wouters EF, van Diejen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *Eur Respir J.* 1996;9(8):1736-1742.
- [12] Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. *Cancer Lett.* 2015;358(1):1-7.
- [13] Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. In: *StatPearls.* StatPearls Publishing; 2024.
- [14] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. *Am J Gastroenterol.* 2017;112(1):18-35.
- [15] Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. *CMAJ.* 2005;172(3):367-379.
- [16] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44-56.
- [17] Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. *Nat Med.* 2022;28(1):31-38.
- [18] Klein T, Mitchell S, Weber H. AI-Powered Blood Test Analysis: Clinical Validation and Global Health Intelligence. *Kantesti AI Research.* 2026. DOI: 10.5281/zenodo.18175532.
- [19] Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. *Nature.* 1990;345(6272):229-233.
- [20] Landsteiner K. Individual differences in human blood. *Science.* 1931;73(1894):403-409.
- [21] Avent ND, Reid ME. The Rh blood group system: a review. *Blood.* 2000;95(2):375-387.
- [22] Westhoff CM. The structure and function of the Rh antigen complex. *Semin Hematol.* 2007;44(1):42-50.
- [23] Mourant AE, Kopec AC, Domaniewska-Sobczak K. The Distribution of the Human Blood Groups and Other Polymorphisms. 2nd ed. Oxford University Press; 1976.
- [24] Mitra R, Mishra N, Rath GP. Blood groups systems. *Indian J Anaesth.* 2014;58(5):524-528.
- [25] Daniels G. Human Blood Groups. 3rd ed. Wiley-Blackwell; 2013.
- [26] Williamson LM, Devine DV. Challenges in the management of the blood supply. *Lancet.* 2013;381(9880):1866-1875.
- [27] Crowther CA, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. *Cochrane Database Syst Rev.* 2000;(2):CD000021.
- [28] Fung KFK, Eason E. No. 133-Prevention of Rh Alloimmunization. *J Obstet Gynaecol Can.* 2018;40(1):e1-e10.
- [29] Klein HG, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine. 12th ed. Wiley-Blackwell; 2014.
- [30] Yazer MH, Triulzi DJ, Shaz B, Kraus T, Zimring JC. Does a febrile reaction to platelets predict a future febrile reaction? *Transfusion.* 2012;52(12):2618-2624.
- [31] Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. *J Thromb Haemost.* 2008;6(1):62-69.
- [32] Barnkob MB, Pottegard A, Stobbe H, et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. *Blood Adv.* 2020;4(20):4990-4993.
- [33] Buttarello M, Plebani M. Automated blood cell counts: state of the art. *Am J Clin Pathol.* 2008;130(1):104-116.

- [34] Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. *Int J Clin Lab Res.* 2000;30(3):115-120.
- [35] Koepke JA, Koepke JF. Reticulocytes. *Clin Lab Haematol.* 1986;8(3):169-179.
- [36] Hillman RS. Characteristics of marrow production and reticulocyte maturation in normal man in response to anemia. *J Clin Invest.* 1969;48(3):443-453.
- [37] Polin V, Coriat R, Perkins G, et al. Iron deficiency: from diagnosis to treatment. *Dig Liver Dis.* 2013;45(10):803-809.
- [38] Young NS. *Aplastic Anemia: Pathophysiology and Treatment.* Cambridge University Press; 2000.
- [39] Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. *Mayo Clin Proc.* 2006;81(1):104-130.
- [40] Markert CL. Lactate dehydrogenase isozymes: dissociation and recombination of subunits. *Science.* 1963;140(3573):1329-1330.
- [41] Wroblewski F, Gregory KF. Lactic dehydrogenase isozymes and their distribution in normal tissues and plasma and in disease states. *Ann N Y Acad Sci.* 1961;94:912-932.
- [42] Burtis CA, Ashwood ER, Bruns DE. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.* 6th ed. Elsevier; 2018.
- [43] Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. *Clin Chem Lab Med.* 2008;46(6):764-772.
- [44] Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. *Dis Markers.* 2015;2015:635670.
- [45] Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. *Am Fam Physician.* 2004;69(11):2599-2606.
- [46] Phillips J, Henderson AC. Hemolytic anemia: evaluation and differential diagnosis. *Am Fam Physician.* 2018;98(6):354-361.
- [47] Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med.* 1993;329(14):987-994.
- [48] Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol.* 2009;27(36):6199-6206.
- [49] Wroblewski F. The clinical significance of transaminase activities of serum. *Am J Med.* 1959;27(6):911-923.
- [50] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. *Am J Gastroenterol.* 2017;112(1):18-35.
- [51] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology.* 2016;64(1):73-84.
- [52] Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol.* 2014;109(7):950-966.
- [53] Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. *J Gastroenterol Hepatol.* 2016;31(5):936-944.
- [54] Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. *Hepatology.* 2005;41(2):380-382.
- [55] Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med.* 2000;342(17):1266-1271.
- [56] Mak CM, Lam CW. Diagnosis of Wilson's disease: a comprehensive review. *Crit Rev Clin Lab Sci.* 2008;45(3):263-290.
- [57] De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. *Clin Chim Acta.* 1957;2(1):70-74.
- [58] Botros M, Sikaris KA. The de Ritis ratio: the test of time. *Clin Biochem Rev.* 2013;34(3):117-130.
- [59] Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. *Am J Gastroenterol.* 1999;94(4):1018-1022.
- [60] Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. *Alcohol Alcohol.* 2004;39(4):336-339.
- [61] Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. *Gastroenterology.* 1988;95(3):734-739.
- [62] Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. *JAMA.* 1980;243(19):1909-1911.
- [63] Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. *Br J Haematol.* 2017;176(3):395-411.
- [64] Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS. The direct antiglobulin test: a critical step in the evaluation of hemolysis. *Am J Hematol.* 2012;87(7):707-709.

- [65] Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging? *Semin Hematol.* 2015;52(4):261-269.
- [66] Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. *Mayo Clin Proc.* 2005;80(7):923-936.
- [67] Camaschella C. Iron-deficiency anemia. *N Engl J Med.* 2015;372(19):1832-1843.
- [68] Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature.* 2017;542(7639):115-118.
- [69] McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. *Nature.* 2020;577(7788):89-94.
- [70] Acevedo A, Merino A, Alferes S, Molina A, Boldu L, Rodellar J. A dataset of microscopic peripheral blood cell images for development of automatic recognition systems. *Data Brief.* 2020;30:105474.
- [71] Matek C, Schwarz S, Spiekermann K, Marr C. Human-level recognition of blast cells in acute myeloid leukaemia with convolutional neural networks. *Nat Mach Intell.* 2019;1:538-544.
- [72] Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. *Stroke Vasc Neurol.* 2017;2(4):230-243.
- [73] Kantesti AI. AI Blood Test Analyzer: Technical Documentation and Clinical Validation Report. Version 4.2. Kantesti AI; 2026.
- [74] Klein T, Mitchell S, Weber H. January 2026 Global Health Intelligence Report: AI-Powered Analysis of 2.5 Million Blood Test Results. Kantesti AI. DOI: 10.5281/zenodo.18175532.
- [75] Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. *Lancet Oncol.* 2019;20(5):e218-e228.
- [76] Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med.* 2019;380(14):1347-1358.
- [77] National Institute for Health and Care Excellence (NICE). Blood transfusion. NICE guideline [NG24]. 2015. Updated 2020.
- [78] European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018;69(1):182-236.
- [79] World Health Organization. Global Health Workforce Statistics. WHO; 2024.
- [80] Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: addressing ethical challenges. *PLoS Med.* 2018;15(11):e1002689.
- [81] Char DS, Shah NH, Magnus D. Implementing machine learning in health care - addressing ethical challenges. *N Engl J Med.* 2018;378(11):981-983.

Source Material: This peer-reviewed article is based on the comprehensive educational guide published at <https://kantesti.net/blood-types-reticulocytes-hematology-markers-guide>. The original content was developed by the Kantesti AI Medical Advisory Board under the leadership of Dr. Thomas Klein, MD, with contributions from Prof. Dr. Hans Weber, PhD and medical review by Dr. Sarah Mitchell, MD, PhD.

How to Cite: Klein, T., Weber, H., & Mitchell, S. (2026). Understanding Blood Types, Reticulocytes & Essential Hematology Markers: A Comprehensive Review. *Kantesti AI Research*. DOI: 10.6084/m9.figshare.31333819